Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2014-001704-22
    Sponsor's Protocol Code Number:CCD-05993AA1-08
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2018-02-22
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2014-001704-22
    A.3Full title of the trial
    A 52-week, Double Blind, Double dummy, Randomized, Multinational, Multicentre, 2-arm Parallel Group, active Controlled Clinical Trial of fixed combination of beclomethasone dipropionate plus formoterol fumarate plus Glycopyrronium bromide administered via pMDI (CHF 5993) versus indacaterol/glycopyrronium (Ultibro®) via DPI in patients with Chronic Obstructive Pulmonary Disease
    Studio clinico controllato con farmaco attivo, della durata di 52 settimane, in doppio cieco, doppio dummy, randomizzato, multinazionale, multicentrico, a gruppi paralleli a 2 bracci, della combinazione fissa di beclometasone dipropionato più formoterolo fumarato più glicopirrolato bromuro somministrata via pMDI (CHF 5993) a confronto con indacaterolo/glicopirronio (Ultibro®) somministrato via DPI in pazienti con broncopneumopatia cronica ostruttiva
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Clinical study that compares the treatment with CHF 5993, a combination of 3 active ingredients, vs Ultibro in patients with Chronic Obstructive Pulmonary Disease.
    Sperimentazione clinica che prevede il confronto tra il trattamento con un farmaco, CHF 5993, che è la combinazione fissa di 3 principi attivi, e Ultibro in soggetti affetti da broncopneumopatia cronica ostruttiva
    A.3.2Name or abbreviated title of the trial where available
    TRIBUTE
    TRIBUTE
    A.4.1Sponsor's protocol code numberCCD-05993AA1-08
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorCHIESI FARMACEUTICI S.P.A.
    B.1.3.4CountryItaly
    B.3.1 and B.3.2Status of the sponsorNon-Commercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportChiesi Farmaceutici S.p.A.
    B.4.2CountryItaly
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationChiesi Farmaceutici S.p.A.
    B.5.2Functional name of contact pointClinical Project Manager
    B.5.3 Address:
    B.5.3.1Street AddressVia Palermo 26/A
    B.5.3.2Town/ cityParma
    B.5.3.3Post code43122
    B.5.3.4CountryItaly
    B.5.4Telephone number+39 0521 1689281
    B.5.5Fax number+39 0521 279333
    B.5.6E-mailf.ferrari.consultant@chiesi.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameCHF 5993 pMDI
    D.3.4Pharmaceutical form Pressurised inhalation, solution
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMP
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNBeclometasone Dipropionato
    D.3.9.1CAS number 5534-09-8
    D.3.9.2Current sponsor codeSUB00681MIG
    D.3.9.3Other descriptive nameBeclometasone Dipropionato
    D.3.9.4EV Substance CodeSUB00681MIG
    D.3.10 Strength
    D.3.10.1Concentration unit µg microgram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number100
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNFormoterolo Fumarato
    D.3.9.1CAS number 43229-80-7
    D.3.9.2Current sponsor codeSUB02257MIG
    D.3.9.3Other descriptive nameFF
    D.3.9.4EV Substance CodeSUB02257MIG
    D.3.10 Strength
    D.3.10.1Concentration unit µg microgram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number6
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNGlicopirrolato Bromuro
    D.3.9.1CAS number 596-51-0
    D.3.9.2Current sponsor codeSUB07951MIG
    D.3.9.3Other descriptive nameGlicopirrolato Bromuro
    D.3.9.4EV Substance CodeSUB07951MIG
    D.3.10 Strength
    D.3.10.1Concentration unit µg microgram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number12.5
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name ULTIBRO BREEZHALER - 85 MCG/43 MCG POLVERE PER INALAZIONE CAPSULA RIGIDA - USO INALATORIO - BLISTER (PA/ALU/PVC-ALU) 96(4 CONFEZIONI DI 24X1) CAPSULE + 4 INALATORI
    D.2.1.1.2Name of the Marketing Authorisation holderNOVARTIS EUROPHARM LTD
    D.2.1.2Country which granted the Marketing AuthorisationItaly
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameUltibro Breezhaler
    D.3.4Pharmaceutical form Inhalation powder, hard capsule
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMP
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNIndacaterolo
    D.3.9.1CAS number 312753-06-3
    D.3.9.2Current sponsor code312753-06-3
    D.3.9.4EV Substance CodeSUB30138
    D.3.10 Strength
    D.3.10.1Concentration unit µg microgram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number85
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNGlicopirronio Bromuro
    D.3.9.1CAS number 596-51-0
    D.3.9.2Current sponsor code596-51-0
    D.3.9.4EV Substance CodeSUB02381MIG
    D.3.10 Strength
    D.3.10.1Concentration unit µg microgram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number43
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboPressurised inhalation, solution
    D.8 Placebo: 2
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboPressurised inhalation, solution
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Chronic Obstructive Pulmonary Disease (COPD)
    Broncopneumopatia cronica ostruttiva (BPCO)
    E.1.1.1Medical condition in easily understood language
    Difficulty breathing as a result of the narrowing of airways (Obstruction of airflow)
    Difficoltà a respirare come risultato di un restringimento delle viee aeree (ostruzione delle vie aeree)
    E.1.1.2Therapeutic area Diseases [C] - Respiratory Tract Diseases [C08]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10009033
    E.1.2Term Chronic obstructive pulmonary disease
    E.1.2System Organ Class 10038738 - Respiratory, thoracic and mediastinal disorders
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To demonstrate the superiority of CHF 5993 pMDI over Ultibro® in terms of moderate and severe COPD exacerbation rate over 52 weeks of treatment.
    Dimostrare la superiorità di CHF 5993 pMDI rispetto a Ultibro® in termini di tasso di riacutizzazione di BPCO moderata e grave nell'arco di 52 settimane di trattamento.
    E.2.2Secondary objectives of the trial
    To evaluate the effect of CHF 5993 pMDI on other lung function parameters, patient’s health status and clinical outcome measures.
    To assess the safety and the tolerability of the study treatments.
    Valutare l'efficacia di CHF 5993 pMDI su altri parametri di funzionalità polmonare, sullo stato di salute del paziente e sulle misure di esito clinico.
    Valutare la sicurezza e la tollerabilità dei trattamenti in studio.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Male and female adults aged ≥ 40 years with written informed consent obtained prior to any study-related procedure.
    2. Patients with a diagnosis of severe or very severe COPD airflow obstruction (according to GOLD guidelines, updated 2014) at least 12 months before the screening visit.
    3. Current smokers or ex-smokers who quit smoking at least 6 months prior to screening visit, with a smoking history of at least 10 pack years [pack-years = (number of cigarettes per day x number of years)/20].
    4. A post-bronchodilator FEV1 < 50% of the predicted normal value and a post-bronchodilator FEV1/FVC ratio < 0.7. [Post bronchodilator means at least 10-15 min after 4 puffs (4 x 100 mcg) of salbutamol pMDI].
    If this criterion is not met at screening, the test can be repeated once before randomisation visit.
    5. A documented history of at least one exacerbation in the 12 months preceding the screening visit.

    A COPD exacerbation will be defined according to the following:
    “A sustained worsening of the patient’s condition (dyspnoea, cough and/or sputum production/purulence), from the stable state and beyond normal day-to-day variations, that is acute in onset and necessitates a change in regular medication in a patient with underlying COPD that includes prescriptions of systemic corticosteroids and/or antibiotics or need for hospitalization”.

    Also documented visits to an emergency department due to COPD exacerbation are considered acceptable to fulfil this criterion.
    6. Patients under double therapy for at least 2 months prior to screening. Double therapy will be defined by treatment with any of the following:
    - Orally inhaled corticosteroids and long-acting β-agonist or
    - Orally inhaled corticosteroids and long-acting muscarinic antagonist or
    - Orally inhaled long-acting β-agonist and inhaled long-acting muscarinic antagonist or

    Patients under monotherapy with long-acting muscarinic antagonist for at least 2 months prior to screening.
    7. Symptomatic patient at screening with a CAT score ≥ 10.
    8. A cooperative attitude and ability to use correctly the pMDI inhalers and Breezhaler® inhalers.
    9. A cooperative attitude and ability to use correctly the spacer AeroChamber PlusTM Flow-Vu antistatic. The criterion on spacer applies only to patients who are using a spacer for the administration of their COPD medications at screening.
    10. A cooperative attitude and ability to use correctly electronic devices with COPD questionnaire.
    1. Adulti di sesso maschile e femminile di età ≥ 40 anni con consenso informato scritto ottenuto prima di qualsiasi procedura correlata allo studio.
    2. Pazienti con una diagnosi di ostruzione del flusso aereo per BPCO grave o molto grave (secondo le linee guida GOLD aggiornate nel 2014) almeno 12 mesi prima della visita di screening.
    3. Fumatori attuali o ex-fumatori che hanno smesso di fumare almeno sei mesi prima della visita di screening, con una storia di fumo di almeno 10 anni-pacchetto [anni-pacchetto = (numero di sigarette al giorno x numero di anni)/20].
    4. VEMS post-broncodilatatore < 50% del valore normale atteso e un rapporto VEMS/CVF < 0,7. [Post-broncodilatatore significa almeno 10-15 min dopo 4 puff (4 x 100 mcg) di salbutamolo con pMDI].
    Se questo criterio non è soddisfatto allo screening, il test può essere ripetuto una volta prima della visita di randomizzazione.
    5. Almeno una riacutizzazione documentata nell'anamnesi dei 12 mesi precedenti la visita di screening.

    Una riacutizzazione della BPCO sarà definita secondo quanto segue:
    “Prolungato peggioramento delle condizioni del paziente (dispnea, tosse e/o produzione di espettorato/purulenza) rispetto allo stato stabile a al di là delle normali variazioni giornaliere, che insorge acutamente e richiede una modificazione del trattamento abituale in un paziente affetto da BPCO sottostante tale da includere la prescrizione di corticosteroidi sistemici e/o antibiotici o la necessità di ospedalizzazione”.

    Anche le visite documentate presso un reparto di pronto soccorso a causa della riacutizzazione della BPCO sono considerate accettabili per soddisfare questo criterio.
    6. Pazienti in doppia terapia per almeno due mesi prima dello screening. La doppia terapia sarà definita come il trattamento con una delle seguenti associazioni:
    - Corticosteroidi inalatori orali e β-agonista a lunga durata d'azione oppure
    - Corticosteroidi inalatori orali e antagonista muscarinico a lunga durata d'azione oppure
    - β-agonista inalatore orale a lunga durata d'azione e antagonista muscarinico inalatore a lunga durata d'azione

    Pazienti in monoterapia con antagonista muscarinico a lunga durata d'azione per almeno 2 mesi prima dello screening.
    7. Paziente sintomatico allo screening con un punteggio CAT ≥ 10.
    8. Atteggiamento collaborativo e capacità di usare correttamente gli inalatori pMDI e Breezhaler®.
    9. Atteggiamento collaborativo e capacità di usare correttamente il distanziatore AeroChamber PlusTM Flow-Vu antistatico. Il criterio relativo al distanziatore si applica esclusivamente ai pazienti che utilizzano un distanziatore per la somministrazione dei farmaci per la BPCO allo screening.
    10. Atteggiamento collaborativo e capacità di usare correttamente dispositivi elettronici con il questionario sulla BPCO.
    E.4Principal exclusion criteria
    1. Pregnant or lactating women and all women physiologically capable of becoming pregnant (i.e. women of childbearing potential) UNLESS are willing to use one or more of the following reliable methods of contraception:
    a. Placement of an intrauterine device (IUD) or intrauterine system (IUS)
    b. Hormonal contraception (implantable, patch, oral, injected)
    c. Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical vaults/caps) with spermicidal foam/gel/film/cream/suppository.
    d. Male sterilization (with the appropriate post-vasectomy documentation of the absence of sperm in the ejaculate).
    Reliable contraception should be maintained throughout the study until last study visit.
    “True abstinence” is acceptable only if it is in line with the preferred and usual lifestyle of the patient.
    Pregnancy testing will be carried out during the course of the study in all women of childbearing potential: serum pregnancy test will be performed at screening and end of treatment, urine pregnancy test will be performed at all visits except the last one.
    Any postmenopausal women (physiologic menopause defined as “12 consecutive months of amenorrhea”) or women permanently sterilized (e.g. tubal occlusion, hysterectomy or bilateral salpingectomy) can be enrolled in the study.
    2. Patients with a current clinical diagnosis of asthma with a physician-judged need for inhaled or oral corticosteroid therapy
    3. Patients requiring use of the following medications:
    a. A course of systemic steroids longer than 3 days for COPD exacerbation in the 4 weeks prior to screening.
    b. A course of antibiotics for COPD exacerbation longer than 7 days in the 4 weeks prior to screening.
    c. PDE4 inhibitors in the 4 weeks prior to screening.
    d. Use of antibiotics for a lower respiratory tract infection (e.g pneumonia) in the 4 weeks prior to screening.
    4. COPD exacerbation requiring prescriptions of systemic corticosteroids and/or antibiotics or hospitalization during the run-in period.
    5. Patients treated with non-cardioselective β-blockers in the month preceding the screening visit or during the run-in period. Those patients may enter the study after non-selective β-blockers withdrawal and/or cardio selective β-blockers intake for at least 10 days before randomization.
    6. Patients treated with long-acting antihistamines unless taken at stable regimen at least 2 months prior to screening and to be maintained constant during the study, or if taken as PRN.
    7. Patients requiring long term (at least 12 hours daily) oxygen therapy for chronic hypoxemia.
    8. Known respiratory disorders other than COPD which may impact the efficacy of the study drug according to the investigator’s judgment. This can include but is not limited to -1 antitrypsin deficiency, active tuberculosis, lung cancer, bronchiectasis, sarcoidosis, lung fibrosis, pulmonary hypertension and interstitial lung disease.
    9. Patients who have clinically significant cardiovascular condition such as, but not limited to, unstable ischemic heart disease, NYHA Class III/IV left ventricular failure, acute ischemic heart disease in the last year prior to study screening, history of sustained cardiac arrhythmias or sustained and non-sustained cardiac arrhythmias diagnosed in the last 6 months (sustained means lasting more than 30 seconds and or ending only with external action, and or leads to hemodynamic collapse; non-sustained means > 3 beats < 30 seconds, and or ending spontaneously, and or asymptomatic), impulse conduction high degree blocks, patients with ICD.
    10. Patients with atrial fibrillation (AF):
    • Paroxysmal atrial fibrillation
    • Persistent: AF episode either lasts longer than 7 days or requires termination by cardioversion, either with drugs or by direct current cardioversion (DCC) within 6 months from screening
    • Long standing Persistent: defined as continuous atrial fibrillation diagnosed in the previous 6 months and/or without a rhythm control strategy
    • Permanent: episode lasting for at least 6 months with a resting ventricular rate ≥ 100 beats/min controlled with a rate control strategy (i.e. selective β-blocker, calcium channel blocker, pacemaker placement, digoxin or ablation therapy).
    11. An abnormal and clinically significant 12-lead ECG that results in active medical problem which may impact the safety of the patient according to investigator’s judgement.
    Patients whose electrocardiogram (12-lead ECG) shows QTcF >450 ms for males or QTcF >470 ms for females at screening visit are not eligible (not applicable for patient with pacemaker).
    12. Medical diagnosis of narrow-angle glaucoma, clinically relevant prostatic hypertrophy or bladder neck obstruction that in the opinion of the investigator would prevent use of anticholinergic agents.
    13. History of hypersensitivity to M3 Antagonists, β2-agonist, corticosteroids or any of the excipients contained in any of the formulations used in the trial which may raise contra-indications or impact the efficacy of th
    1. Donne in gravidanza o in allattamento e tutte le donne fisiologicamente in grado di rimanere incinte (ovvero donne in età fertile) A MENO CHE siano disposte ad usare uno o più dei seguenti metodi contraccettivi affidabili:
    a. Inserimento di un dispositivo intrauterino (IUD) o sistema intrauterino (IUS)
    b. Contraccezione ormonale (impiantabile, cerotto, orale, iniettata)
    c. Metodi contraccettivi di barriera: profilattico o pessario occlusivo (diaframma o coppette/cappucci cervicali) con schiuma/gel/pellicola/crema/supposta spermicida.
    d. Sterilizzazione maschile (con la documentazione postero-vasectomia appropriata sull'assenza di spermatozoi nell'eiaculato).
    La contraccezione affidabile deve proseguire per l'intera durata dello studio sino all'ultima visita del medesimo.
    La “vera astinenza” è accettabile solo se in linea con lo stile di vita preferito e abituale del/della paziente.
    Test di gravidanza saranno condotti durante il periodo di svolgimento dello studio su tutte le donne in età fertile: il test di gravidanza sierologico sarà eseguito allo screening e alla fine del trattamento, il test di gravidanza urinario sarà eseguito in tutte le visite ad eccezione dell'ultima.
    Tutte le donne in postmenopausa (menopausa fisiologica definita come “12 mesi consecutivi di amenorrea”) o le donne sterilizzate in modo permanente (per es. occlusione delle tube, isterectomia o salpingectomia bilaterale) possono essere arruolate nello studio.
    2. Pazienti con una diagnosi clinica corrente di asma che necessitino, secondo il parere del medico, di una terapia con corticosteroidi inalatori o da assumere per via orale.
    3. Pazienti che necessitino dell'uso dei seguenti farmaci:
    a. Un ciclo di steroidi sistemici per più di 3 giorni per la riacutizzazione della BPCO nelle 4 settimane precedenti lo screening.
    b. Un ciclo di antibiotici per più di sette giorni per una riacutizzazione della BPCO nelle 4 settimane precedenti lo screening.
    c. Inibitori della PDE4 nelle 4 settimane precedenti lo screening.
    d. Uso di antibiotici per un'infezione alle basse vie aeree (per es. polmonite) nelle 4 settimane precedenti lo screening
    4. Riacutizzazione della BPCO che richieda la prescrizione di corticosteroidi e/o antibiotici sistemici o l'ospedalizzazione durante il periodo di run-in.
    5. Pazienti trattati con β-bloccanti non cardioselettivi nel mese precedente la visita di screening o durante il periodo di run-in. Tali pazienti possono entrare nello studio dopo la sospensione dei β-bloccanti non selettivi e/o l'assunzione di β-bloccanti cardioselettivi per almeno 10 giorni prima della randomizzazione.
    6. Pazienti trattati con antistaminici a lunga durata d'azione a meno che tali farmaci non siano stati assunti ad un regime stabile per almeno 2 mesi prima della screening e che siano mantenuti costanti durante lo studio, o assunti al bisogno.
    7. Pazienti che richiedano l'ossigenoterapia a lungo termine (almeno 12 ore al giorno) per ipossiemia cronica.
    8. Disturbi respiratori noti diversi dalla BPCO che, a parere dello sperimentatore, possano incidere sull'efficacia del farmaco in studio. Questi possono includere, a titolo esemplificativo ma non esaustivo: deficit di alfa 1-antitripsina, tubercolosi attiva, neoplasia polmonare, bronchiectasia, sarcoidosi, fibrosi polmonare, ipertensione polmonare e malattia interstiziale polmonare.
    9. Pazienti con un disturbo cardiovascolare clinicamente significativo come, a titolo esemplificativo ma non esaustivo, cardiopatia ischemica instabile, insufficienza ventricolare sinistra di classe NYHA III/IV, cardiopatia ischemica acuta nell'ultimo anno prima dello screening dello studio, anamnesi positiva per aritmie cardiache sostenute o aritmie cardiache sostenute e non sostenute diagnosticate negli ultimi 6 mesi (il termine sostenute indica aritmie di durata superiore a 30 secondi e/o terminanti solo con un'azione esterna, e/o che portano al collasso emodinamico; il termine non sostenute indica > 3 battiti < 30 secondi, e/o aritmie che terminano in modo spontaneo, e/o asintomatiche), blocchi di grado elevato della conduzione di impulsi, pazienti con DCI.
    10. Pazienti con fibrillazione atriale (FA):
    • Fibrillazione atriale parossistica
    • Persistente: episodio di FA che duri più di 7 giorni o che richieda di essere risolto mediante cardioversione, con farmaci o cardioversione a corrente continua (DCC, direct current cardioversion) entro 6 mesi dallo screening
    • Persistente di lunga durata: definita come fibrillazione atriale continua diagnosticata nei 6 mesi precedenti e/o senza una strategia di controllo del ritmo
    • Permanente: episodio che dura per almeno 6 mesi con una frequenza ventricolare a riposo ≥ 100 battiti/min controllata con una strategia di controllo della frequenza (per es. β-bloccante selettivo, calcioantagonista, impianto di pacemaker, terapia con digossina o ablativa).
    11. Un ECG a 12 derivazioni anomalo e clinicamente significativo che evidenzi un problema medico in atto che, a parere de
    E.5 End points
    E.5.1Primary end point(s)
    Moderate and severe COPD exacerbation rate over 52 weeks of treatment.
    Tasso di riacutizzazione di BPCO moderata e grave oltre le 52 settimane di trattamento.
    E.5.1.1Timepoint(s) of evaluation of this end point
    Study duration.
    Durata dello studio.
    E.5.2Secondary end point(s)
    Time and rate of COPD exacerbation
    Change from baseline pre-dose morning FEV1, FVC and FEV1 response
    Change in SGRQ, CAT, EXACT-PRO score
    Use of rescue medication and nocturnal symptoms
    Il tempo e la velocità di riacutizzazione di BPCO
    Variazione dal basale del VEMS e CVF mattutino pre-somministrazione.
    Variazione del punteggio dei questionari SGRQ, CAT, EXACT-PRO
    L'uso di farmaci di soccorso e sintomi notturni
    E.5.2.1Timepoint(s) of evaluation of this end point
    Study duration
    Durata dello studio
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other Yes
    E.8.1.7.1Other trial design description
    double dummy
    double dummy
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Yes
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned10
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA151
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Argentina
    Chile
    Mexico
    Peru
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LSLV
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years1
    E.8.9.1In the Member State concerned months10
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years1
    E.8.9.2In all countries concerned by the trial months10
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1Number of subjects for this age range: 1
    F.1.1.1In Utero Information not present in EudraCT
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) Information not present in EudraCT
    F.1.1.3Newborns (0-27 days) Information not present in EudraCT
    F.1.1.4Infants and toddlers (28 days-23 months) Information not present in EudraCT
    F.1.1.5Children (2-11years) Information not present in EudraCT
    F.1.1.6Adolescents (12-17 years) Information not present in EudraCT
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 1000
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 534
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception Yes
    F.3.3.2Women of child-bearing potential using contraception No
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state99
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 1223
    F.4.2.2In the whole clinical trial 1534
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Patients will receive appropriate medical care after termination of the study.
    I pazienti riceveranno assistenza adeguata dopo il termine della loro partecipazione allo studio.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2015-05-08
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2015-04-22
    P. End of Trial
    P.End of Trial StatusCompleted
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 04 00:14:43 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA